| Record ID | marc_columbia/Columbia-extract-20221130-031.mrc:99458174:3854 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-031.mrc:99458174:3854?format=raw |
LEADER: 03854cam a2200721Ia 4500
001 15085518
005 20220507231408.0
006 m o d
007 cr cn|||||||||
008 120621s2012 fluad obs 001 0 eng d
035 $a(OCoLC)ocn802054865
035 $a(NNC)15085518
040 $aE7B$beng$epn$cE7B$dOCLCO$dOHS$dNLE$dDEBBG$dOCLCF$dOCLCQ$dUAB$dYDXCP$dCAUOI$dIDEBK$dCRCPR$dOCLCQ$dERL$dUUM$dUKMGB$dWYU$dUWO$dOCLCO$dOCLCA$dLEAUB$dAU@$dSFB$dOCLCO
015 $aGBB7A4804$2bnb
016 7 $a018380226$2Uk
019 $a808961126$a1058696217$a1067229002$a1096215625$a1110587324$a1162171776
020 $a9781439814499$q(e-book)
020 $a143981449X$q(e-book)
020 $z9781439814482
020 $z9781138199118$q(paperback)
020 $z1439814481
020 $a1138199117
020 $a9781138199118
024 7 $a10.1201/b12125$2doi
035 $a(OCoLC)802054865$z(OCoLC)808961126$z(OCoLC)1058696217$z(OCoLC)1067229002$z(OCoLC)1096215625$z(OCoLC)1110587324$z(OCoLC)1162171776
037 $aTANDF_200988$bIngram Content Group
050 4 $aRC267$b.C55 2012eb
060 4 $aQZ 16
082 04 $a616.994060724$223
049 $aZCUA
245 00 $aClinical trials in oncology /$cStephanie Green [and others].
250 $a3rd ed.
260 $aBoca Raton, Fla. :$bCRC Press,$c2012.
300 $a1 online resource (xi, 241 pages :) :$billustrations.
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aChapman and Hall/CRC interdisciplinary statistics series
500 $a"A Chapman & Hall book."
504 $aIncludes bibliographical references and index.
505 0 $a1. Introduction -- 2. Statistical concepts -- 3. The design of clinical trials -- 4. Phase I and phase I/II trials -- 5. Phase II trials -- 6. Phase III trials -- 7. Data management and quality control -- 8. Reporting of results -- 9. Pitfalls -- 10. Exploratory analyses -- 11. Summary and conclusions.
520 $aThe third edition provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background.
650 0 $aCancer$xResearch$xStatistical methods.
650 0 $aClinical trials.
650 12 $aClinical Trials as Topic$xstandards
650 12 $aNeoplasms$xtherapy
650 22 $aClinical Trials as Topic
650 22 $aData Interpretation, Statistical
650 6 $aCancer$xRecherche$xMéthodes statistiques.
650 6 $aÉtudes cliniques.
650 7 $aCancer$xResearch$xStatistical methods.$2fast$0(OCoLC)fst00845511
650 7 $aClinical trials.$2fast$0(OCoLC)fst00864429
655 0 $aElectronic books.
655 2 $aStatistics
655 4 $aElectronic books.
655 7 $aStatistics.$2lcgft
655 7 $aStatistiques.$2rvmgf
700 1 $aGreen, Stephanie.
776 0 $z9781439814482
776 0 $z9781439814499
830 0 $aInterdisciplinary statistics.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15085518$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS